Detalhe da pesquisa
1.
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
Blood
; 143(4): 336-341, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647641
2.
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Blood
; 142(23): 1960-1971, 2023 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647654
3.
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Am J Hematol
; 99(2): E32-E36, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994196
4.
Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.
Int J Mol Sci
; 24(5)2023 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36902217
5.
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome.
Blood
; 140(22): 2407-2411, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35960851
6.
FLT3-ITD signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescue.
Haematologica
; 107(4): 783-784, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34348456
7.
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
J Clin Oncol
; : JCO2301599, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38427924
8.
Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas.
Clin Lymphoma Myeloma Leuk
; 23(3): e190-e194, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36707275
9.
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia.
Cancer Discov
; 13(7): 1720-1747, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37012202
10.
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
J Clin Oncol
; 38(30): 3506-3517, 2020 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32687450
11.
Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?
Leuk Lymphoma
; 62(13): 3073-3077, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34348073